Tags

Type your tag names separated by a space and hit enter

Serum C-reactive protein in the differential diagnosis of ovarian masses.
Eur J Obstet Gynecol Reprod Biol. 2009 Nov; 147(1):65-8.EJ

Abstract

OBJECTIVE

A number of serum tumor markers have been investigated to aid clinicians in the differential diagnosis of ovarian masses. Serum C-reactive protein (CRP) is a widely used biomarker of inflammation and has been previously shown to be a promising biomarker in patients with ovarian cancer.

STUDY DESIGN

In a retrospective single-center study, we evaluated serum CRP in 576 patients with benign and in 242 patients with malignant (ovarian tumors of low malignant potential [LMP]: n=44, epithelial ovarian cancer [EOC]: n=198) ovarian masses. Results were correlated to clinical data.

RESULTS

Median (25th, 75th percentiles) serum CRP in patients with benign ovarian tumors, with ovarian tumors of LMP, and with EOC were 0.5 (0.5, 0.6)mg/dL, 0.5 (0.5, 0.9)mg/dL, and 1.36 (0.5, 4.9)mg/dL, respectively (p<0.001). In the subgroup of patients with EOC, serum CRP significantly correlated with FIGO stage (p<0.001), residual tumor mass (p<0.001), and patients' age (p=0.04), but not with tumor grade (p=0.2) and histologic type (p=0.4). In univariable and multivariable models including serum CRP, serum CA 125, and patients' age, serum CRP independently predicted the presence of malignant ovarian masses (p<0.0001; Odds Ratio [OR] 5.3, 95% Confidence Interval [CI] 3.8-7.4). Serum CRP had a sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for identifying malignant ovarian masses of 49.8%, 84.1%, 57.1%, and 79.8%, respectively.

CONCLUSION

Serum CRP is associated with the presence of malignant ovarian tumors independent of serum CA 125 and patients' age and can therefore be used as additional diagnostic marker in the differential diagnosis of ovarian masses.

Authors+Show Affiliations

Department of Laboratory Medicine, Wilhelminenspital, Vienna, Austria.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19619929

Citation

Hefler-Frischmuth, Katrin, et al. "Serum C-reactive Protein in the Differential Diagnosis of Ovarian Masses." European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 147, no. 1, 2009, pp. 65-8.
Hefler-Frischmuth K, Hefler LA, Heinze G, et al. Serum C-reactive protein in the differential diagnosis of ovarian masses. Eur J Obstet Gynecol Reprod Biol. 2009;147(1):65-8.
Hefler-Frischmuth, K., Hefler, L. A., Heinze, G., Paseka, V., Grimm, C., & Tempfer, C. B. (2009). Serum C-reactive protein in the differential diagnosis of ovarian masses. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 147(1), 65-8. https://doi.org/10.1016/j.ejogrb.2009.06.010
Hefler-Frischmuth K, et al. Serum C-reactive Protein in the Differential Diagnosis of Ovarian Masses. Eur J Obstet Gynecol Reprod Biol. 2009;147(1):65-8. PubMed PMID: 19619929.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum C-reactive protein in the differential diagnosis of ovarian masses. AU - Hefler-Frischmuth,Katrin, AU - Hefler,Lukas A, AU - Heinze,Georg, AU - Paseka,Veronika, AU - Grimm,Christoph, AU - Tempfer,Clemens B, Y1 - 2009/07/19/ PY - 2009/04/11/received PY - 2009/05/26/revised PY - 2009/06/10/accepted PY - 2009/7/22/entrez PY - 2009/7/22/pubmed PY - 2010/1/29/medline SP - 65 EP - 8 JF - European journal of obstetrics, gynecology, and reproductive biology JO - Eur J Obstet Gynecol Reprod Biol VL - 147 IS - 1 N2 - OBJECTIVE: A number of serum tumor markers have been investigated to aid clinicians in the differential diagnosis of ovarian masses. Serum C-reactive protein (CRP) is a widely used biomarker of inflammation and has been previously shown to be a promising biomarker in patients with ovarian cancer. STUDY DESIGN: In a retrospective single-center study, we evaluated serum CRP in 576 patients with benign and in 242 patients with malignant (ovarian tumors of low malignant potential [LMP]: n=44, epithelial ovarian cancer [EOC]: n=198) ovarian masses. Results were correlated to clinical data. RESULTS: Median (25th, 75th percentiles) serum CRP in patients with benign ovarian tumors, with ovarian tumors of LMP, and with EOC were 0.5 (0.5, 0.6)mg/dL, 0.5 (0.5, 0.9)mg/dL, and 1.36 (0.5, 4.9)mg/dL, respectively (p<0.001). In the subgroup of patients with EOC, serum CRP significantly correlated with FIGO stage (p<0.001), residual tumor mass (p<0.001), and patients' age (p=0.04), but not with tumor grade (p=0.2) and histologic type (p=0.4). In univariable and multivariable models including serum CRP, serum CA 125, and patients' age, serum CRP independently predicted the presence of malignant ovarian masses (p<0.0001; Odds Ratio [OR] 5.3, 95% Confidence Interval [CI] 3.8-7.4). Serum CRP had a sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for identifying malignant ovarian masses of 49.8%, 84.1%, 57.1%, and 79.8%, respectively. CONCLUSION: Serum CRP is associated with the presence of malignant ovarian tumors independent of serum CA 125 and patients' age and can therefore be used as additional diagnostic marker in the differential diagnosis of ovarian masses. SN - 1872-7654 UR - https://www.unboundmedicine.com/medline/citation/19619929/Serum_C_reactive_protein_in_the_differential_diagnosis_of_ovarian_masses_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0301-2115(09)00413-8 DB - PRIME DP - Unbound Medicine ER -